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Abstract  
Objectives 
Cyclophosphamide induction regimens are effective for ANCA-associated vasculitis (AAV), 
but are associated with infections, malignancies and infertility. Mycophenolate mofetil 
(MMF) has shown high remission rates in small studies of AAV.. 
 
Methods 
We conducted a randomised controlled trial to investigate whether MMF was non-inferior 
to cyclophosphamide for remission-induction in AAV. 140 newly diagnosed patients were 
randomly assigned to MMF or pulsed cyclophosphamide. All patients received the same oral 
glucocorticoid regimen and were switched to azathioprine following remission. The primary 
endpoint was remission by 6 months requiring compliance with the tapering glucocorticoid 
regimen. Patients with an eGFR<15mls/min were excluded from the study. 
 
Results 
At baseline, ANCA subtype, disease activity and organ involvement were similar between 
groups. Non-inferiority was demonstrated for the primary remission endpoint, which 
occurred in 47 patients (67%) in the MMF group and 43 patients (61%) in the 
cyclophosphamide group (Risk Difference (RD) 5.7%, 90%CI -7.5% to19%). Following 
remission, more relapses occurred in the MMF group (23 patients, 33%) compared to the 
cyclophosphamide group (13 patients, 19%) (IRR 1.97, 95%CI 0.96 to4.23, p=0.049). In MPO-
ANCA patients, relapses occurred in 12% of the cyclophosphamide group and 15% of the 
MMF group. In PR3-ANCA patients, relapses occurred in 24% of the cyclophosphamide group 
and 48% of the MMF group. Serious infections were similar between groups (26% MMF 
group, 17% cyclophosphamide group) (OR1.67 (95%CI 0.68 to 4.19, p=0.3).  
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Conclusion 
MMF was non-inferior to cyclophosphamide for remission-induction in AAV, but resulted in 
higher relapse rate.  
(Clinical trials.gov number NCT00414128) 
 
Key words – ANCA-associated vasculitis, induction therapy, cyclophosphamide, 
mycophenolate, randomised trial 
Key messages 
What is already known 
 Cyclophosphamide remains the first line induction remission treatment for AAV for 
many patients but is linked with infertility, infection and malignancy. 
 Mycophenolate mofetil (MMF) has been shown in small studies to have high 
remission rates. 
What does this study add 
 This study is the largest to show with sufficient power that remission rates with 
MMF are non-inferior to pulsed cyclophosphamide but this maybe associated with a 
higher rate of relapse. 
How might this impact on future clinical practice 
 MMF induction therapy in patients at low risk of relapse, such as those with MPO-
ANCA,  may be a suitable alternative to cyclophosphamide. 
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BACKGROUND 
ANCA-associated vasculitis (AAV) [1], which includes Granulomatosis with polyangiitis (GPA) 
and microscopic polyangiitis (MPA), are rare potentially life-threatening multisystem 
autoimmune diseases. They are frequently grouped together for the purpose of treatment 
trials given their similar initial responses to standard therapy [2, 3]. Treatment for ANCA-
associated vasculitis comprises remission induction and maintenance regimens [2]. The 
European League Against Rheumatism (EULAR) guidelines for the treatment of AAV suggest 
the use of cyclophosphamide or rituximab for remission induction therapy in new-onset 
organ-threatening or life-threatening AAV in combination with glucocorticoids[4]. 
Cyclophosphamide with high dose glucocorticoids has been standard remission induction 
therapy for severe ANCA-associated vasculitis for over 30 years with remission rates of 80-
90% [5, 6] and a current one year mortality of 10-25% [7]. However; cyclophosphamide is 
toxic causing infertility and malignancy. Rituximab is associated with similar remission 
induction rates to those achieved with cyclophosphamide and similar relapse rates over 18-
24 months follow-up [8-11]. However, the biological effect of rituximab is long and variable, 
and rituximab has been associated with hypogammaglobulinaemia in ANCA-associated 
vasculitis [12]. Due to its high cost the use of rituximab is restricted in some countries[13, 
14]. For non-organ threatening AAV EULAR recommends methotrexate or Mycophenolate 
mofetil (MMF) in combination with glucocorticoids, although the level of evidence is rated as 
1B, requiring further studies[4]. Methotrexate has similar efficacy to cyclophosphamide for 
remission induction in non-severe ANCA-associated vasculitis, but its toxicity precludes use 
in renal impairment [15, 16]. Mycophenolate mofetil is an alternative oral 
immunosuppressant with lymphocyte selective suppressive effects with a short duration of 
action, can be used in renal disease and unlike cyclophosphamide is not associated with 
urothelial malignancy or infertility. Small studies have suggested that MMF has efficacy for 
remission induction in ANCA-associated vasculitis, particularly in MPO-ANCA disease [17, 
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18].  Understanding the role of MMF as a remission induction agent in ANCA-associated 
vasculitis remains important. We conducted a randomised trial of adult and paediatric 
patients to investigate whether MMF was non-inferior to cyclophosphamide for remission 
induction in new patients with ANCA-associated vasculitis. 
 
METHODS 
Study design and patients 
This trial was an open-label, two group, parallel design, randomised, non-inferiority trial 
involving 132 adult patients from 21 sites in six countries in Europe, Australia and New 
Zealand, and eight paediatric patients from four sites in the UK. All patients/parents 
provided written informed consent; and written assent where appropriate. Inclusion in this 
study required a new diagnosis of active ANCA-associated vasculitis (GPA or MPA)[1]  with 
either a positive ANCA or histologically proven disease (see protocol for full inclusion 
details). Patients were excluded if they were aged < 6 years, had imminently life threatening 
vasculitis, rapidly declining renal function or an eGFR less than 15mls/min/m2 or had 
received >2 weeks of oral cyclophosphamide or MMF or more than 1 pulse of IV CYC 
(15mg/kg). The trial protocol is available at 
http://vasculitis.org/images/documents/mycyc.pdf.  
Patients were allocated in a 1:1 ratio to MMF or cyclophosphamide using a concealed 
system of minimization by: age greater than 60 years, the planned use of additional therapy 
with plasma exchange or solumedrol>0.5g at randomisation, estimated glomerular filtration 
rate (eGFR) less than 30mls/min/m2 or greater than or equal to 30ml/min/m2 with an 
allocation probability of 0.8. Although the minimization procedure did not include site as a 
stratification factor, the degree of balance of treatments within the sites was reasonable 
(Supplementary table 1) 
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The trial was sponsored by Cambridge University Hospitals NHS Foundation Trust. Vifor 
Pharma (previously Aspreva Pharmaceuticals) provided a research grant to cover the trial 
and MMF costs. The trial protocol was designed by the ‘MYCYC’ trial steering committee, 
and received ethical and regulatory approval in each participating country. The trial was 
conducted according to the EU clinical trials directive (Directive 2001 EU/20/EC) (EUDRACT 
2006-001663-33). The trial was approved by Oxfordshire Research Ethics Committee B (ref 
number 06/Q1605/120). Trial data is stored by the trial management committee at 
Addenbrooke’s Hospital, UK.  
Supplementary table 1 
Centre MMF N= Cyc N= 
Adelaide 1 5 
Birmingham 4 6 
Birmingham 
paediatrics  
1 
Cambridge 19 14 
Aberdeen 1 
 
Alder Hey 
paediatrics 
1 
 
Oxford 1 2 
Auckland 
 
2 
Coventry 1 1 
Barcelona 6 4 
Fundacion 4 1 
Germain Del Rey 1 1 
Girona 1 
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Belgium 7 7 
Bradford 1 3 
Canberra 3 4 
Edinburgh 2 2 
Great Ormond 
Street paediatrics 
2 3 
Hammersmith 1 
 
Nottingham 2 3 
Nottingham 
paediatrics 
1 
 
Parma 2 6 
Prague 2 2 
Sweden 6 2 
Reading 1 1 
Total 70 70 
 
Abbreviations: MMF, mycophenolate mofetil limb; CYC, cyclophosphamide limb; N, 
number of participants 
Treatments 
After randomisation, both groups received the same oral tapering glucocorticoid regimen 
(prednisolone 1mg/kg/day initially, reducing to 5mg/day at the end of 6 months 
supplementary figure 1D). Adult patients in the MMF group received MMF 2g/day, with 
dose increases to 3g/day permitted for uncontrolled disease at four weeks. Patients aged 
less than 17 years received a body surface area based MMF dosing regimen. Patients in the 
cyclophosphamide group received intravenous pulsed cyclophosphamide as given in the 
CYCLOPS trial (15mg/kg 2-3 weekly with reductions for age and renal function) [6, 9]  . All 
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patients were switched from their assigned study treatment to oral azathioprine 
2mg/kg/day after remission had been achieved, between 3-6 months. Azathioprine with 
prednisolone 5mg/day was continued until study end at 18 months.  
 
Outcomes  
The primary outcome was remission by six months. Remission was defined as the absence of 
disease activity with a BVAS 2003 of zero on two consecutive occasions at least one month 
apart and adherence to the prednisolone taper. Secondary efficacy endpoints were time to 
remission, remission by six months irrespective of glucocorticoid adherence, progressive 
disease, relapse, cumulative glucocorticoid dosing, change in eGFR, Vasculitis Damage Index 
(VDI)[19], and ANCA positivity at six months. Planned subgroup analyses were the effect of 
eGFR, age and additional intravenous methylprednisolone and/or plasma exchange pre-
randomisation on remission, and ANCA subtypes, on remission and relapse. Safety outcomes 
were serious adverse events, serious infections, ESRD, death, malignancy, cardiovascular, 
thromboembolic and serious disease related events. Outcomes were adjudicated by a 
committee blinded to study group assignment. 
 
Assessments  
Assessments were performed at 0, 1, 1.5, 3, 4.5, 6, 9, 12, and 18 months and at the time of a 
relapse. Relapses could only occur after an initial remission (absence of disease activity, 
irrespective of glucocorticoid compliance, at any time during trial follow-up). Patients who 
did not achieve an initial remission were excluded from relapse analyses. Relapses were 
defined as the recurrence or new appearance of any disease activity, as reflected by a BVAS 
2003 > 0. Major relapse required the presence of one or more major BVAS items. Renal 
function was assessed using eGFR, calculated using the 4 variable Modified Diet in Renal 
Disease (MDRD) equation in adults[20] or Haycock-Schwartz formula in patients aged less 
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than 16 years[21]. End Stage Renal Disease (ESRD) was defined as dialysis dependence for six 
weeks or more without subsequent recovery of renal function. Progressive disease was 
defined as on-going disease activity of sufficient severity to necessitate therapy escalation 
with a change in immunosuppression or intravenous methylprednisolone before remission. 
Serious adverse events were collected as defined by the European Medicines Agency and 
Food and Drug Administration. ANCA negativity was determined by the reference range of 
the local laboratory for both indirect immunofluorescence and enzyme linked 
immunosorbant assays. 
 
 
Statistical Analysis 
The sample size estimate was based on a non-inferiority design. We assumed a remission 
rate of 85% with cyclophosphamide and specified a 12% absolute risk difference as the non-
inferiority margin (i.e. remission rate <73%) for MMF. Using these assumptions, we 
calculated that 124 patients were required to meet non-inferiority for the primary remission 
endpoint with a power of 80%, and a significance level of 5% in a non-inferiority test[22]. 
Allowing for a 10% drop out rate we recruited 140 patients. 
 
All endpoint analyses were by intention to treat with an additional pre-specified per protocol 
analysis of the primary endpoint.  The primary and secondary remission endpoints (non-
inferiority) were assessed by calculating the risk difference (RD) of remission with 
corresponding two-sided 90% confidence intervals, consistent with the CONSORT extension  
for reporting of non-inferiority trials[23]. For the primary analyses, no attempts were made 
to impute missing data.  Data were censored at withdrawal, loss to follow-up or death. Time 
to event analyses of remission (non-inferiority) were performed using a Cox proportional 
hazards model with a hazard ratio (HR) of 0.85 as the non-inferiority margin.  Relapse rates 
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(superiority) were compared by calculating the incidence rate ratio (relapses per patient per 
year) and corresponding 95% confidence interval with significance estimates derived from 
the binomial distribution test. For safety and other efficacy endpoints comparison of 
proportions was performed using the Fisher mid-p test, as recommended[24] . All 
continuous variables are presented as mean ± SD or median (IQR) as appropriate to their 
distribution, and categorical variables are presented as count (%). All analyses were 
conducted using Stata SE version 15 (College Station TX). 
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RESULTS 
Patients 
Between March 2007 and July 2011, 140 patients were enrolled in the study (66 adults and 
four children in each treatment group). The 4 children recruited to the CYC group were ages 
14, 16, 14, and 15 years old and the 4 recruited to the MMF group were 10,16, 12 and 13 
years old. All patients received their allocated treatment and were retained for the primary 
analysis. By the end of the 6 month treatment period, four in each group had died, and three 
in the MMF group and two in the cyclophosphamide group had been lost to follow-up or had 
withdrawn consent (Figure 1, Table 1). Fifty eight patients received at least 6 pulses of 
cyclophosphamide, of whom 23 had 7-10 pulses. Cyclophosphamide was terminated early in 
six (2 infection, 2 intolerance 1 ESRD, 1 no reason) and six died or withdrew from the trial 
prior to 3 months. The maximum dose of MMF received by patients was 2g in 76%, 6% 
received >2g and 18% received <2g. MMF was withdrawn due to intolerance in 4 patients 
due to  incontinence, rash, diarrhoea, reason not specified. At 18 months 52 patients, 26 
from each study group, were not receiving azathioprine. This was due to drug intolerance in 
11 patients in the CYC group and 15 patients in the MMF group. 
 
 
Table 1. Baseline characteristics of the patients at trial entry. 
Variable Mycophenolate 
mofetil group 
(N=70) 
Cyclophosphamide 
group 
(N=70) 
Age (yrs) – median (IQR) 60 (48-70) 61 (53-68) 
Paediatric <18 years (%) 4   (6) 4   (6) 
Male sex – no. (%) 41 (59) 33 (47) 
Diagnosis – no. (%)   
13 
 
GPA 
MPA 
47 (67) 
23 (33) 
44 (63) 
26 (37) 
ANCA – no. (%) 
PR3 or cANCA 
MPO or pANCA 
Negative 
 
41 (59) 
28 (40) 
1 (1) 
 
42 (60) 
26 (37) 
2 (3) 
ANCA ELISA – no. (%) 
PR3-ANCA 
MPO-ANCA 
Negative 
 
40 (57) 
27 (39) 
3 (4) 
 
42 (60) 
26 (37) 
2 (3) 
eGFR at entry, ml/min/m2 - median (IQR) 
All patients 
Patients with renal disease 
 
51 (29-92) 
47 (27-70) 
 
51 (31-79) 
46 (29-74) 
Organs involvement* – no. (%) 
Renal 
Lung 
ENT 
 
57 (81) 
30 (43) 
41 (59) 
 
57 (81) 
35 (50) 
38 (54) 
BVAS# – median (IQR) 19 (13-25) 18 (14-23) 
CRP (mg/L) - median (IQR) 22 (7.5-52) 19 (5-83) 
ESR (mm/hr) – median (IQR) 54 (31-98) 59 (33-90) 
Cyclophosphamide pre-randomisation 
Patients - no. (%) 
Total dose (grams) – median (IQR) 
 
17 (24) 
1 (0.55-1.1) 
 
22 (31) 
1 (0.6-1.07) 
IV methylprednisolone pre-randomisation  
Patients - no. (%) 
 
41 (59) 
 
35 (50) 
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Total dose (grams) – median (IQR) 1.5 (1.5-3) 1.5 (1.5-2) 
Plasma exchange pre-randomisation 
Patients - no. (%) 
Total exchanges – median (IQR) 
 
8 (11) 
5 (5-7) 
 
4 (6) 
7 (6-7) 
 
* Renal involvement is defined as one or more renal BVAS items present at entry excluding 
hypertension alone. Lung and ENT require one or more lung or ENT BVAS items present at 
entry respectively. #Baseline BVAS data was missing in 1 subject in the MMF group.  
 
Primary outcome 
The primary endpoint of remission with glucocorticoid compliance within 6 months occurred 
in 47 patients, including 1 child, (67%) in the MMF and 43 (61%), including 1 child, in the 
cyclophosphamide groups (Risk Difference (RD) 5.7%, 90%CI -7.5% to19%). Given the 
specified non-inferiority margin of -12%, the lower bound of the 90% CI of -7.5% established 
non-inferiority (Figure 2).  
 
In a pre-specified analysis restricted to per-protocol treated patients, 43 remissions (74%) 
occurred in 58 mycophenolate patients, compared to 33 remissions (62%) in 53 
cyclophosphamide patients (RD 11.9%, 90% CI -2.6% to 26.3%, non inferior) (Figure 2). There 
was no evidence of interaction by PR3 ANCA positivity, age, renal function and the use of 
additional induction therapies with the primary endpoint (Figure 2).  
 
Secondary efficacy outcomes 
Secondary efficacy outcomes are summarised in Figure 3, supplementary Table 2 and 
supplementary Figure 1. The time to primary remission in the MMF group (median 91 days, 
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IQR 44-95) was non-inferior to the cyclophosphamide group (median 87 days, IQR 42-91), 
since the lower bound of the 90%CI did not cross 0.85 (HR 1.27 [90%CI 0.89 to 1.79]). 
Remission irrespective of steroid compliance within 6 months occurred in 61 patients (87%) 
in the MMF and 55 (79%) in the cyclophosphamide groups (RD 8.6%, 90%CI -1.8% to 19%). 
Remission at any time during trial follow up irrespective of steroid compliance occurred in 
63 patients (90%), including 2 children, in the MMF and 64 (92%), including 2 children, of the 
cyclophosphamide groups (RD -1.4%, 90%CI -9.5% to 6.6%). 
 
Table S2. Efficacy Outcomes 
 MMF group  
(n=70) 
CYC group  
(n=70) 
Point estimates Non-
inferiority 
margin 
Significance 
Primary endpoint      
Primary remission – no. 
(%) 
47 (67) 43 (61) RD 5.7%, 90%CI -
7.5% to 19% 
-12% Non-inferior 
Per protocol* analysis – 
no (%) 
43/58 () 33 (53) RD 11.9%, 90%CI -
2.6% to 26.3% 
-12% Non-inferior 
Secondary endpoints      
Remission      
§Time to primary 
remission by (6 months) 
  HR 1.27,  
90%CI 0.89 – 1.79, p 
= 0.27 
0.85 Non-inferior 
Remission by 6 months 
irrespective of steroid 
compliance – no. (%) 
61 (87) 55 (79) RD 8.6%,  
90%CI -1.8% to19% 
-12% Non-inferior 
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Remission at any time 
irrespective of steroid 
compliance – no. (%) 
63 (90) 64 (91) RD -1.4%,  
90%CI -9.5% to 6.6% 
-12% Non-inferior 
 
Progressive disease – 
no. (%) 
5 (7) 8 (11) – Superiority 0.56 
 
Relapse – no. (%) 
 
23 (33) 
 
13 (19) 
 
IRR 1.97,  
95%CI 0.96 to 4.23 
Superiority 
 
0.049 
 
All patients 
Time to first relapse 
 
 
 
 
HR 2.14,  
95%CI 1.07 – 4.31 
Superiority  
 
0.03 
0.03 
Major relapses 4 (6) 3 (4) IRR 1.48, 95%CI 
0.25–10.13 
Superiority 0.63 
Time to major relapse   HR 2.4, 95%CI 0.44 
to 13.13 
Superiority 0.31 
 
Minor relapses 19(27) 10(14) IRR 2.11, 95%CI 
0.93–5.09 
Superiority 0.053 
Time to minor relapse   HR 2.09, 95%CI 0.97 
to 4.5 
Superiority 0.059 
RD – Risk Difference; HR – Hazard Ratio; IRR – Incidence Risk Ratio.  
*The per protocol analysis was performed as an additional analysis for the primary endpoint 
and included patients who adhered to their assigned study treatment regimen (see 
appendix) for the first 6 weeks of the trial and did not receive additional intravenous 
steroids or immunomodulatory treatments. 29 patients were excluded from the per 
protocol analysis (MMF 12, CYC 17). § For the time to remission analysis, remissions were 
defined as for the primary endpoint. 
There were more relapses after remission in the mycophenolate group (23/63 patients; 4 
major and 19 minor relapses) compared with the cyclophosphamide group (13/64 patients; 
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3 major and 10 minor relapses, IRR 1.97, 95% CI 0.96 to 4.23, p=0.049). Relapse free survival 
was shorter in the mycophenolate group (HR 2.14, 95% CI 1.07 to 4.31, p=0.03). A post-hoc 
subgroup analysis found the higher relapse rate in MMF patients was accounted for by more 
relapses in PR3 ANCA patients, but not MPO ANCA patients. (Supplementary Figure 2). There 
was no evidence that the effect of MMF on relapse differed by ANCA subtype (p=0.52 for 
interaction).  
 
Remission irrespective of steroid compliance within 6 months occurred in 61 patients (87%) 
in the MMF and 55 (79%) in the cyclophosphamide groups (RD 8.6%, 90%CI -1.8% to 19%). 
Remission at any time during trial follow up irrespective of steroid compliance occurred in 
63 patients (90%) in the MMF and 64 (92%) of the cyclophosphamide groups (RD -1.4%, 
90%CI -9.5% to 6.6%).  
 
Progressive disease necessitating rescue therapy before remission occurred in five patients 
(7%) in the MMF and eight (11%) in the cyclophosphamide groups (p=0.56). At 6 months, 26 
of 65 (40%) patients in the MMF group were ANCA negative, and 21 of 65 (32%) patients in 
the cyclophosphamide group were ANCA negative (RR 1.23, 95%CI 0.78 to 1.96, p=0.36). 
 
There was no statistically significant difference in cumulative glucocorticoid exposure during 
the trial (MMF 6194 ± 317 mg, CYC 5800 ± 234 mg, p=0.32) (Supplementary Figure 1a).  Two 
patients in both groups progressed to ESRD and eGFR at 18 months did not differ between 
groups (MMF group 68±4 ml/min, cyclophosphamide group 64±4 ml/min, p=0.46) 
(Supplementary Figure 1b). There was no difference in disease and treatment related 
damage assessed by the vasculitis damage index at study end between the two groups 
(MMF=1, IQR 1 to 3; CYC=2, IQR 1 to 3; p=0.80). 
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Safety outcomes 
 
Serious adverse events occurred in 35 in the MMF (50% patients, 73 events) and 28 in the 
cyclophosphamide groups (40% patients, 64 events) and are summarised in Table 2. There 
were no significant differences in serious infections, death, thromboembolism, malignancy 
or serious disease related events between the two groups. 
 
Table 2. Serious Adverse Events 
 Mycophenolate mofetil group  
(n=70) 
Cyclophosphamide group  
(n=70) 
Significance 
 All events 
 
Patients with 
≥1 event 
All events Patients with ≥1 
event 
 
 
 No. No. (%) No. No. (%) 
 
 
All serious adverse events  
 
73 35 (50) 64 28 (40) P=0.30 
Serious events by category 
 
     
Infections 
 
29 18 (26) 16 12 (17) P=0.30 
End stage renal disease 
 
2 2 (3) 2 2 (3) P=1.0 
Death 
 
5 5 (7) 4 4 (6) P=1.0 
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Malignancy 
 
1 1 (1) 1 1 (1) P=1.0 
Cardiovascular 
 
6 3 (4) 6 5 (7) P=0.72 
Disease related events 
 
16 10 (14) 9 7 (10) P=0.61 
Thromboembolism 
 
2 2 (3) 2 2 (3) P=1.0 
 
Five mycophenolate patients died (7%) (causes of death were cardiac n=1, infections n=2 
and other n=2) and four cyclophosphamide patients died (6%) (causes of death were cardiac 
n=1, infections n=2 and other n=1) (OR 1.27 (95% CI 0.26 to 6.68, p=1.0). Median age at 
death was 75 years (range 73 to 82 years) in the MMF group and 83 years (range 63 to 85 
years) in the cyclophosphamide group. Malignancies were liver metastases of unknown 
primary in a 74 year old in the mycophenolate group and a malignant melanoma in a 63 year 
old in the cyclophosphamide group. 
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Discussion 
In this randomised trial of remission induction in ANCA-associated vasculitis, excluding 
patients on dialysis or with life-threatening disease, MMF was non-inferior to pulsed 
cyclophosphamide. The relatively low remission rate for the primary outcome can be 
attributed to the stringent requirement for adherence to glucocorticoid taper as shown by 
others,[8] and the higher rate of the secondary endpoint of remission irrespective of 
glucocorticoid adherence is consistent with previous reports where the glucocorticoid taper 
was not a component of the remission definition. [6, 25] Our results demonstrate that MMF 
represents an alternative to cyclophosphamide for remission induction in AAV. This study 
provides further evidence to support the EULAR guidelines on management of AAV. 
 
Our findings of the efficacy of MMF for remission induction are consistent with previous 
MMF induction studies in AAV[18, 26, 27]. After remission, relapses occurred earlier and 
more frequently in the MMF group (33%) compared to the cyclophosphamide group (19%). 
Although this was a secondary outcome and the trial was not designed or powered to detect 
differences in relapse rate, this observation is consistent with the increase in early relapses 
observed with methotrexate compared to cyclophosphamide[15], higher relapse risk with 
lower cumulative cyclophosphamide exposure[28], and the higher rate of relapse with MMF 
compared to AZA when used for maintenance therapy[29]. While treatment with MMF may 
be associated with a higher risk of relapse compared to pulsed cyclophosphamide, this 
increased risk may be acceptable to avoid the potential adverse effects of cyclophosphamide 
particularly when the baseline risk of relapse is low (e.g. in patients that are MPO-ANCA 
positive) or if rituximab is unavailable.   
 
The use of MMF alongside standard dose glucocorticoids offers advantages over 
cyclophosphamide in terms of fertility preservation for younger patients and potentially 
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lower malignancy rates in elderly populations at greatest risk[30]. Unlike rituximab (an 
approved alternative to cyclophosphamide for severe ANCA-associated vasculitis), MMF is 
an oral drug, has a short duration of action, and unlike methotrexate, can be used in 
moderate or severe renal disease and was not associated with slower time to remission 
compared to cyclophosphamide [15]. However, there were no differences in this study in 
the number of adverse events between the two groups. 
 
Our trial has several notable strengths. It is the largest randomised trial in AAV to assess the 
use of MMF for remission induction. Patients were recruited from 21 countries, and the trial 
cohort was representative of other trial populations in AAV. This is the first randomised trial 
in AAV to include children, although the small number of paediatric participants (n=8) limits 
the inferences we might draw concerning relative efficacy of MMF in this population. The 
primary endpoint was achieved in 1 of 4 paediatric patients in both CYC and MMF groups 
and response rates were similar in the MMF and CYC groups in children. Compliance was a 
contributory factor to the lower remission rate in children, and because of the small sample 
size we have not drawn conclusions of efficacy in this subpopulation.  
 
The strengths of our trial should be viewed against its limitations. The trial was not blinded, 
although the similar rates of glucocorticoid adherence and exposure, progressive disease, 
rescue therapy requirement, ANCA negativity and the rates of ESRD is reassuring. Treating 
clinicians were allowed to include plasma exchange or additional solumedrol at entry; 
however there were no differences in additional treatments used between the two groups.  
The short follow up of 18 months in this study may have reduced the ability to detect the 
true effect on relapse and malignancy rates in the longer term. It should be noted in another 
study MMF was inferior to azathioprine for remission maintenance after cyclophosphamide 
induction, with more relapses in the MMF group, [29]. Following remission induction all 
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patients in our trial received azathioprine and glucocorticoid maintenance therapy. There is 
limited evidence for using azathioprine as induction therapy in AAV. It has been used in 
addition to corticosteroids for newly diagnosed non-severe eosinophilic granulomatosis with 
polyangiitis, microscopic polyangiitis , or polyarteritis nodosa, however the addition of 
azathioprine in these patients did not improve remission rates or reduce relapse [31].  
 
Since initiation of the trial, it has become common to use rituximab as an alternative to 
cyclophosphamide induction therapy, which may question the use of MMF as an alternative 
induction therapy. However, rituximab is expensive and its use is restricted in many 
countries, for example in New Zealand treatment of patients with MPO-ANCA vasculitis must 
first have failed with cyclophosphamide or MMF[14] prior to rituximab use. Alternative 
effective low cost induction therapies maybe required in some cases.  
 
This study provides evidence that MMF is a potential alternative to cyclophosphamide for 
remission induction in non-life threatening, AAV, particularly in patients with low predicted 
relapse risk, such as the elderly that are MPO positive. With increasing remission induction 
treatment options for AAV, stratified treatment approaches are indicated in order to 
optimise long term outcomes. 
 
Acknowledgements 
Sponsorship for this trial was provided by Cambridge University Hospitals NHS Foundation 
Trust. Funding for this trial and the cost of the mycophenolate mofetil was provided in the 
form of a research grant from Vifor Pharma (previously Aspreva Pharamaceuticals). We are 
very grateful to the trial adjudication committee for blinded data adjudication, and to Dr 
Pani Gopaluni and Dr Mark McClure for independent data adjudication. We are also grateful 
to Dr Afzal Chaudhry for the trial database design, all the trial investigators, sub-
23 
 
investigators, research nurses, and all the patients who participated in this study. Support 
was also provided by the NIHR Cambridge Biomedical Research Centre. The study was 
conducted within the Birmingham and Cambridge National Institute for Health Research 
(NIHR) / Wellcome Trust (WT) Clinical Research Facilities (CRF) at these sites. The views 
expressed are those of the authors and not necessarily those of the NHS, the NIHR or the 
Department of Health. PB acknowledges support from the Great Ormond St Hospital Clinical 
Research Facility and NIHR Great Ormond St Biomedical Research Centre, and Great Ormond 
St Hospital Children’s Charity. TFH is supported by NIHR 14/49/127, 16/167/120 and 
17/27/11, and by the NIHR Cambridge Biomedical Research Centre. MCC and GEF 
acknowledge support from Ministerio de Economía , Industria y Competitividad (SAF 
14/57708-R and 17/88275-R) and Instituto de Salud Carlos III (PI 15/00092 co-funded by 
FEDER and Juan Rodés program), respectively.
24 
 
Competing Interests 
RJ: consulting for ChemoCentryx. Academic secondment with GlaxoSmithKline 2011–2013. 
US: consulting for Genentech/Roche. PAM: Consulting for Actelion, Alexion, Bristol Myers 
Squibb, ChemoCentryx, Genzyme/Sanofi, GlaxoSmithKline, Genentech/Roche, PrincipioBio. 
Research support from Actelion, Bristol Myers Squibb, Celgene, ChemoCentryx, 
Genentech/Roche, GlaxoSmithKline. DJ: consulting for Alexion, ChemoCentryx, 
Genzyme/Sanofi, GlaxoSmithKline, Genentech/Roche, and Takeda. Research support from 
ChemoCentryx, Genentech/Roche, Genzyme/Sanofi, Medimmune, and GlaxoSmithKline. 
LH: consulting for ChemoCentryx, honorarium Roche. 
TFH: Research support from GlaxoSmithKline, Otauka and AstroZeneca 
 
 
 
  
25 
 
References 
1. Jennette JC: Overview of the 2012 revised International Chapel Hill Consensus 
Conference nomenclature of vasculitides. Clin Exp Nephrol 2013, 17(5):603-606. 
2. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, Hauser T, 
Hellmich B, Jayne D, Kallenberg CG et al: EULAR recommendations for the 
management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009, 
68(3):310-317. 
3. Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L, Jayne 
D, Mahr A, Merkel PA, Raspe H et al: EULAR recommendations for conducting 
clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil 
cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007, 66(5):605-617. 
Epub 2006 Dec 2014. 
4. Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, Hellmich B, Holle JU, 
Laudien M, Little MA et al: EULAR/ERA-EDTA recommendations for the 
management of ANCA-associated vasculitis. Ann Rheum Dis 2016, 75(9):1583-1594. 
5. Jayne D: Treatment of ANCA-associated systemic small-vessel vasculitis. APMIS 
Suppl 2009(127):3-9. 
6. de Groot K, Harper L, Jayne D, Flores Suarez L, Gregorini G, Gross W, al e, , Group). 
EEVS: Pulse versus daily oral cyclophosphamide for induction of remission in 
antineutrophil cytoplasmic antibody--associated vasculitis. A randomized trial.  . 
Ann Intern Med 2009, 150:670-680. 
7. Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, Hoglund P, Jayne D, 
Luqmani R, Mahr A et al: Long-term patient survival in ANCA-associated vasculitis. 
Ann Rheum Dis 2011, 70(3):488-494. 
8. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St 
Clair EW, Turkiewicz A, Tchao NK et al: Rituximab versus cyclophosphamide for 
ANCA-associated vasculitis. N Engl J Med 2010, 363(3):221-232. 
9. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, 
Segelmark M, Tesar V, van Paassen P et al: Rituximab versus cyclophosphamide in 
ANCA-associated renal vasculitis. N Engl J Med 2010, 363(3):211-220. 
10. Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St 
Clair EW, Fessler BJ, Ding L et al: Efficacy of remission-induction regimens for ANCA-
associated vasculitis. N Engl J Med 2013, 369(5):417-427. 
11. Jones RB, Furuta S, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage 
CO, Segelmark M, Tesar V et al: Rituximab versus cyclophosphamide in ANCA-
associated renal vasculitis: 2-year results of a randomised trial. Ann Rheum Dis 
2015, 74(6):1178-1182. 
12. Roberts DM, Jones RB, Smith RM, Alberici F, Kumaratne DS, Burns S, Jayne DR: 
Rituximab-associated hypogammaglobulinemia: incidence, predictors and 
outcomes in patients with multi-system autoimmune disease. J Autoimmun 2015, 
57:60-65. 
13. England N: Clinical Commissioning Policy: Rituximab for the treatment of ANCA-
associated vasculitis in adults. https://wwwenglandnhsuk/commissioning/wp-
content/uploads/sites/12/2015/01/a13-ritux-anca-vasculpdf 2015. 
14. PHARMAC: Widening of funding restrictions for rituximab. 
https://wwwpharmacgovtnz/news/notification-2014-02-19-rituximab-eltrombopag/ 
2014. 
15. de Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, Gross WL, 
Luqmani R, Jayne DR: Randomized trial of cyclophosphamide versus methotrexate 
26 
 
for induction of remission in early systemic antineutrophil cytoplasmic antibody-
associated vasculitis. Arthritis Rheum 2005, 52(8):2461-2469. 
16. Faurschou M, Westman K, Rasmussen N, de Groot K, Flossmann O, Hoglund P, Jayne 
DR, European Vasculitis Study G: Brief Report: long-term outcome of a randomized 
clinical trial comparing methotrexate to cyclophosphamide for remission induction 
in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. 
Arthritis Rheum 2012, 64(10):3472-3477. 
17. Han F, Liu G, Zhang X, Li X, He Q, He X, Li Q, Wang S, Wang H, Chen J: Effects of 
mycophenolate mofetil combined with corticosteroids for induction therapy of 
microscopic polyangiitis. Am J Nephrol 2011, 33(2):185-192. 
18. Hu W, Liu C, Xie H, Chen H, Liu Z, Li L: Mycophenolate mofetil versus 
cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal 
involvement. Nephrol Dial Transplant 2008, 23(4):1307-1312. Epub 2007 Dec 1308. 
19. Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO, Adu D: 
Development and initial validation of the Vasculitis Damage Index for the 
standardized clinical assessment of damage in the systemic vasculitides. Arthritis 
Rheum 1997, 40(2):371-380. 
20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method 
to estimate glomerular filtration rate from serum creatinine: a new prediction 
equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 
130(6):461-470. 
21. Haycock GB, Schwartz GJ, Wisotsky DH: Geometric method for measuring body 
surface area: a height-weight formula validated in infants, children, and adults. J 
Pediatr 1978, 93(1):62-66. 
22. Makuch R, Simon R: Sample size requirements for evaluating a conservative 
therapy. Cancer Treat Rep 1978, 62(7):1037-1040. 
23. Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG, Group C: Reporting of 
noninferiority and equivalence randomized trials: extension of the CONSORT 2010 
statement. JAMA 2012, 308(24):2594-2604. 
24. Fagerland MW, Lydersen S, Laake P: Statistical analysis of contingency tables. CRC 
press 2017, 1st edition p 174. 
25. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, Ekstrand A, 
Gaskin G, Gregorini G, de Groot K et al: A randomized trial of maintenance therapy 
for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J 
Med 2003, 349(1):36-44. 
26. Silva F, Specks U, Kalra S, Hogan MC, Leung N, Sethi S, Fervenza FC: Mycophenolate 
mofetil for induction and maintenance of remission in microscopic polyangiitis 
with mild to moderate renal involvement--a prospective, open-label pilot trial. Clin 
J Am Soc Nephrol 2010, 5(3):445-453. 
27. Stassen PM, Cohen Tervaert JW, Stegeman CA: Induction of remission in active anti-
neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil 
in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis 2007, 
66(6):798-802. Epub 2006 Dec 2019. 
28. Harper L, Morgan MD, Walsh M, Hoglund P, Westman K, Flossmann O, Tesar V, 
Vanhille P, de Groot K, Luqmani R et al: Pulse versus daily oral cyclophosphamide 
for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann 
Rheum Dis 2012, 71(6):955-960. 
29. Hiemstra TF, Walsh M, Mahr A, Savage CO, de Groot K, Harper L, Hauser T, Neumann 
I, Tesar V, Wissing KM et al: Mycophenolate mofetil vs azathioprine for remission 
maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a 
randomized controlled trial. Jama 2010, 304(21):2381-2388. 
27 
 
30. Hellmich B, Lamprecht P, Gross WL: Advances in the therapy of Wegener's 
granulomatosis. Curr Opin Rheumatol 2006, 18(1):25-32. 
31. Puechal X, Pagnoux C, Baron G, Quemeneur T, Neel A, Agard C, Lifermann F, Liozon 
E, Ruivard M, Godmer P et al: Adding Azathioprine to Remission-Induction 
Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), 
Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors: 
A Randomized, Controlled Trial. Arthritis & rheumatology (Hoboken, NJ 2017, 
69(11):2175-2186. 
 
  
28 
 
Figure legends 
 
Figure 1. Randomization and inclusion in the analysis at 18 months 
 
 Figure 2. Absolute risk ratio for the primary remission endpoint, per-protocol and sub-group 
analyses.  
The lower bound 90% CI did not cross the non-inferiority margin of 12% for the primary end-
point and per protocol analyses demonstrating non-inferiority. The lower bound 90% CI only 
crossed the non-inferiority margin for patients with GFR<30ml/min but the upper-bound 
90%CI exceeded 0. This would be described as ‘inconclusive’ and given this is a secondary 
analysis of a sub-group we are unable to draw any inference from this other than the p value 
for interaction being non-significant.  The diamonds represent the absolute risk ratio, 
horizontal black lines represent 90% confidence intervals. The left side of blue shaded area 
represents the lower limit of non-inferiority margin (-12%).  
 
Figure 3. Remission and relapse 
a. Time to primary remission 
Primary remission was remission with no disease activity and glucocorticoid protocol 
compliance. Analysis was censored at the first of the following events; remission (first BVAS 
of zero), six month study visit, withdrawal or death.  
b. Time to first relapse  
Relapse could only occur after an initial remission. Remissions for this analysis are not 
restricted to the first 6 months of follow-up, but represent remissions occurring at any time 
point after randomisation irrespective of glucocorticoid compliance. Time to first relapse 
was significantly shorter in the mycophenolate mofetil group.  
 
Figure S1. 
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A. Cumulative steroid exposure 
Boxes represent median (IQR), whiskers represent the nearest adjacents (nearest value to 
1.5 times the IQR from the median). Dots represent outliers. 
 
B. Change in glomerular filtration rate 
Data points represent individual values for change from baseline eGFR (ml/min/m2) over 
actual time. Lines represent the fitted linear regression values of change in eGFR over time. 
 
C. Vasculitis damage index 
The figure shows individual VDI values over time for the two groups. Scatter plots show 
individual values with jitter in both axes for clarity. Lines represent the fitted quadratic 
regression lines for VDI over time. 
 
D. Steroid Taper 
The figure shows the protocolised and actual steroid tapers within each study group. The 
black line represents the protocolised dose by weight (calculated as mean weight of the 
entire trial population x 1 mg/kg) and the stratified lines represent per treatment group 
equivalents (mean doses). This has been restricted to the first 6 months consistent with the 
primary outcome. 
  30 
Figure S2 
c. Time to relapse stratified by ANCA-PR3 and ANCA-MPO subtypes 
More relapses occurred in the MMF group than the cyclophosphamide group. A post-hoc 
subgroup analysis found the higher relapse rate in MMF patients was accounted for by more 
relapses in PR3 ANCA patients, but not MPO ANCA patients. However, the study was not 
designed or powered to detect differences in relapses rates. There was no evidence that the 
effect of MMF on relapse differed by ANCA subtype (p=0.52 for interaction) 
 
 
 
